Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs Eli Lilly And Co — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $61.09 (market cap $44.49B), while Eli Lilly And Co trades at $1,179.27 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 23.4× JPMorgan Nasdaq Equity Premium Income ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Nasdaq Equity Premium Income ETF for 66 Days and Eli Lilly And Co for 93 Days on average.
| JEPQ | LLY | |
|---|---|---|
Market Cap | $44.49B | $1.04T |
Volume | 5,681,789 | 3,064,878 |
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $1.28K |
52-Week Low | $53.77 | $799.57 |
Typical Hold Time | 66 Days | 93 Days |
Enterprise Value | — | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $60.93, down 0.55% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF's covered-call strategy generates substantial monthly income, with recent dividends ranging from $0.57 to $0.70 per share. Recent news highlights JEPQ's 11% estimated annual yield and its positioning in AI-driven tech stocks, though the strategy limits upside potential during strong market rallies.
JEPQ offers high income generation through its Nasdaq-focused covered-call approach, making it attractive for retirees seeking monthly cash flow. However, the strategy caps appreciation potential and faces volatility sensitivity, requiring proper portfolio sizing. Key risks include market volatility dependence and competitive pressure from similar income ETFs with different tax treatments.
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
